Jiangsu Jibeier Pharmaceutical Co Ltd

Jibeier released its 2026 interim report. The company's total operating revenue was 490 million yuan, and net profit attributable to the parent was 99.2384 million yuan, down 33.54% from the same period last year. Net cash inflow from operating activities was 133 million yuan, down 15.18% year-on-year. The company's asset-liability ratio was 8.98%, gross margin was 90.08%, and diluted earnings per share was 0.50 yuan, down 33.33% year-on-year. The number of shareholders was 7,516, and the top ten shareholders held 72.26% of the total share capital.

Jibeier released its 2026 half-year report, with first-half net profit attributable to the parent of 99.24 million yuan, down 33.5% year-on-year. Operating revenue was 490 million yuan, up 7.6% year-on-year; net profit attributable to the parent after deducting non-recurring items was 99.27 million yuan, down 6.9% year-on-year; net operating cash flow was 133 million yuan, down 15.2% year-on-year; earnings per share were 0.4935 yuan. In the second quarter, operating revenue was 263 million yuan, up 4.0% year-on-year; net profit attributable to the parent was 57.24 million yuan, down 42.6% year-on-year; net profit attributable to the parent after deducting non-recurring items was 57.14 million yuan, down 0.3% year-on-year. As of the end of the second quarter, the company's total assets were 2.782 billion yuan, up 2.4% from the end of the previous year; net assets attributable to the parent were 2.515 billion yuan, up 3.5% from the end of the previous year. The company stated that overall operations remained stable, with main products covering multiple therapeutic areas including boosting white blood cells, antihypertension, and enhancing immunity, and it is actively advancing research and development of new drugs in the antidepressant and antitumor fields. The application for production approval of the antidepressant new drug JJH201501 is progressing in an orderly manner, the antitumor new drug JJH201601 has completed subject enrollment for the Phase IIa clinical trial, and the National Medical Products Administration has agreed to conduct a pivotal Phase III study in the third-line biliary tract cancer population.